大細胞型B細胞リンパ腫で再発した人、または以前の治療に反応しなかった人の通常の治療にタゼメトスタットまたはザヌブルチニブを追加する第2相試験
再発/難治性大細胞型B細胞リンパ腫の移植不適格患者におけるタファシタマブベースの治療への標的治療薬の追加に関するランダム化第II相研究
This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell lymphoma that returned or did not respond to earlier treatment. Tazemetostat is in a class of medications called EZH2 inhibitors. It helps to stop the spread of cancer cells. Zanubrutinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells. tafasitamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Lenalidomide is in a class of medications called immunomodulatory agents. It works by helping the bone marrow to produce normal blood cells and by killing abnormal cells in the bone marrow. The addition of tazemetostat or zanubrutinib to tafasitamab and lenalidomide may be able to shrink the cancer or extend the time without cancer symptoms coming back.
調査の概要
状態
条件
詳細な説明
PRIMARY OBJECTIVES:
I. To determine the recommended phase II dose of tafasitamab + lenalidomide + tazemetostat AND of tafasitamab + lenalidomide + zanubrutinib. (Safety Run-in) II. To compare progression-free survival (PFS) of patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) treated with tafasitamab + lenalidomide + tazemetostat vs control (tafasitamab + lenalidomide) AND treated with tafasitamab + lenalidomide + zanubrutinib versus (vs) control. (Randomized Phase II Study)
SECONDARY OBJECTIVES:
I. To estimate the hazard ratio for PFS for control vs. tafasitamab + lenalidomide + tazemetostat in germinal center B-cell (GCB) and non-GCB (activated B-cell [ABC]/unclassified) subsets.
II. To estimate the hazard ratio for PFS for control vs. tafasitamab + lenalidomide + zanubrutinib in GCB and non-GCB (ABC/unclassified) subsets.
III. To estimate progression-free survival (PFS), overall response rate (ORR), complete response rate (CR), partial response rate (PR), duration of response (DOR), event-free survival (EFS), overall survival (OS), in GCB and non-GCB LBCL for each treatment.
IV. To evaluate adverse events within each treatment arm.
OTHER OBJECTIVES:
I. To explore PFS within subgroups defined by molecular profile (e.g., MCD, BN2, N1 and EZB) and genetic subtypes.
II. To explore PFS in the tafasitamab-lenalidomide control arm vs that in matched historical control from L-MIND and realMIND studies.
III. To assess frailty (Cumulative Illness Rating Scale [CIRS] and Timed Get Up and Go [TUG]) and its correlation with outcome.
PRIMARY PATIENT-REPORTED OUTCOMES OBJECTIVE:
I. To compare patient-reported lymphoma-specific symptoms as measured by the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Trial Outcome Index sub-scale at 3 months after randomization between the control arm and each experimental arm (Arm 1 versus Arm 2 and Arm 3 versus Arm 2).
SECONDARY PATIENT-REPORTED OUTCOMES OBJECTIVE:
I. To compare participant-reported toxicity (treatment side effect) symptoms using selected Patient Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE) items between experimental vs control arms.
EXPLORATORY PATIENT-REPORTED OUTCOMES OBJECTIVES:
I. To compare patient-reported quality of life using the FACT-General (G) subscale score and the FACT-Lym total score at 3 months after randomization between the control arm and each experimental arm.
II. To compare quality of life over time between treatment arms from baseline to 12 months after randomization as measured by the FACT-Lym trial outcome index (TOI), FACT-G, and FACT-Lym total score using longitudinal analysis.
BANKING OBJECTIVE:
I. To bank specimens for future correlative studies.
OUTLINE: This is a dose-escalation study of tazemetostat and zanubrutinib.
PART I (SAFETY RUN-IN): Patients are assigned to 1 of 2 arms per treating investigator's choice.
ARM I: Patients receive tafasitamab intravenously (IV), lenalidomide orally (PO), and tazemetostat PO on study. Patients also undergo positron emission tomography/computed tomography (PET/CT) and CT or magnetic resonance imaging (MRI) scans throughout the trial. Patients also have the option to undergo collection of blood samples during screening and on study.
ARM III: Patients receive tafasitamab IV, lenalidomide PO, and zanubrutinib PO on study. Patients also undergo PET/CT and CT or MRI scans throughout the trial. Patients also have the option to undergo collection of blood samples during screening and on study.
PART II: Patients are randomized to 1 of 3 arms.
ARM I: Patients receive tafasitamab IV, lenalidomide PO, and tazemetostat PO on study. Patients also undergo PET/CT and CT or MRI scans throughout the trial. Patients also have the option to undergo collection of blood samples during screening and on study.
ARM II: Patients receive tafasitamab IV and lenalidomide PO on study. Patients also undergo PET/CT and CT or MRI scans throughout the trial. Patients also have the option to undergo collection of blood samples during screening and on study.
ARM III: Patients receive tafasitamab IV, lenalidomide PO, and zanubrutinib PO on study. Patients also undergo PET/CT and CT or MRI scans throughout the trial. Patients also have the option to undergo collection of blood samples during screening and on study.
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Katarina Gasic
- 電話番号:210-677-8808
- メール:kgasic@swog.org
研究連絡先のバックアップ
- 名前:Crystal Miwa
- 電話番号:210-677-8808
- メール:cmiwa@swog.org
研究場所
-
-
Arizona
-
Tucson、Arizona、アメリカ、85719
- 募集
- Banner University Medical Center - Tucson
-
コンタクト:
- Site Public Contact
- メール:UACC-IIT@uacc.arizona.edu
-
主任研究者:
- Krishna Rekha Moturi
-
Tucson、Arizona、アメリカ、85719
- 募集
- University of Arizona Cancer Center-North Campus
-
コンタクト:
- Site Public Contact
- メール:UACC-IIT@uacc.arizona.edu
-
主任研究者:
- Krishna Rekha Moturi
-
-
California
-
Beverly Hills、California、アメリカ、90211
- 募集
- Tower Cancer Research Foundation
-
主任研究者:
- Akil A. Merchant
-
コンタクト:
- Site Public Contact
- メール:towercancerresearch@toweroncology.com
-
Duarte、California、アメリカ、91010
- 募集
- City of Hope Comprehensive Cancer Center
-
コンタクト:
- Site Public Contact
- 電話番号:800-826-4673
- メール:becomingapatient@coh.org
-
主任研究者:
- Alexey V. Danilov
-
Huntington Beach、California、アメリカ、92648
- 募集
- City of Hope Seacliff
-
主任研究者:
- Alexey V. Danilov
-
コンタクト:
- Site Public Contact
- 電話番号:626-256-4673
-
Lancaster、California、アメリカ、93534
- 募集
- City of Hope Antelope Valley
-
コンタクト:
- Site Public Contact
- 電話番号:800-826-4673
- メール:becomingapatient@coh.org
-
主任研究者:
- Alexey V. Danilov
-
Long Beach、California、アメリカ、90813
- 募集
- City of Hope at Long Beach Elm
-
コンタクト:
- Site Public Contact
- 電話番号:877-467-3411
-
主任研究者:
- Alexey V. Danilov
-
Los Angeles、California、アメリカ、90048
- 募集
- Cedars Sinai Medical Center
-
主任研究者:
- Akil A. Merchant
-
コンタクト:
- Site Public Contact
- 電話番号:310-423-8965
-
Newport Beach、California、アメリカ、92660
- 募集
- City of Hope Newport Beach
-
コンタクト:
- Site Public Contact
- 電話番号:877-467-3411
-
主任研究者:
- Alexey V. Danilov
-
South Pasadena、California、アメリカ、91030
- 募集
- City of Hope South Pasadena
-
コンタクト:
- Site Public Contact
- 電話番号:800-826-4673
- メール:becomingapatient@coh.org
-
主任研究者:
- Alexey V. Danilov
-
Torrance、California、アメリカ、90503
- 募集
- City of Hope South Bay
-
コンタクト:
- Site Public Contact
- 電話番号:877-467-3411
-
主任研究者:
- Alexey V. Danilov
-
Upland、California、アメリカ、91786
- 募集
- City of Hope Upland
-
コンタクト:
- Site Public Contact
- 電話番号:800-826-4673
- メール:becomingapatient@coh.org
-
主任研究者:
- Alexey V. Danilov
-
-
Florida
-
Fort Lauderdale、Florida、アメリカ、33308
- 募集
- Holy Cross Hospital
-
主任研究者:
- Tareq Al baghdadi
-
コンタクト:
- Site Public Contact
- メール:eileen.georgi@holy-cross.com
-
Miami Beach、Florida、アメリカ、33140
- 一時停止
- Mount Sinai Medical Center
-
-
Illinois
-
Chicago、Illinois、アメリカ、60637
- 募集
- University of Chicago Comprehensive Cancer Center
-
コンタクト:
- Site Public Contact
- 電話番号:773-702-8222
- メール:cancerclinicaltrials@bsd.uchicago.edu
-
主任研究者:
- Justin P. Kline
-
Chicago、Illinois、アメリカ、60612
- 募集
- University of Illinois
-
コンタクト:
- Site Public Contact
- 電話番号:312-355-3046
-
主任研究者:
- Paul G. Rubinstein
-
Danville、Illinois、アメリカ、61832
- 募集
- Carle at The Riverfront
-
主任研究者:
- Suparna Mantha
-
コンタクト:
- Site Public Contact
- 電話番号:800-446-5532
- メール:Research@Carle.com
-
Effingham、Illinois、アメリカ、62401
- 募集
- Carle Physician Group-Effingham
-
主任研究者:
- Suparna Mantha
-
コンタクト:
- Site Public Contact
- 電話番号:800-446-5532
- メール:Research@carle.com
-
Mattoon、Illinois、アメリカ、61938
- 募集
- Carle Physician Group-Mattoon/Charleston
-
主任研究者:
- Suparna Mantha
-
コンタクト:
- Site Public Contact
- 電話番号:800-446-5532
- メール:Research@carle.com
-
New Lenox、Illinois、アメリカ、60451
- 募集
- UC Comprehensive Cancer Center at Silver Cross
-
コンタクト:
- Site Public Contact
- 電話番号:773-702-8222
- メール:cancerclinicaltrials@bsd.uchicago.edu
-
主任研究者:
- Justin P. Kline
-
Orland Park、Illinois、アメリカ、60462
- 募集
- University of Chicago Medicine-Orland Park
-
コンタクト:
- Site Public Contact
- 電話番号:773-702-8222
- メール:cancerclinicaltrials@bsd.uchicago.edu
-
主任研究者:
- Justin P. Kline
-
Shiloh、Illinois、アメリカ、62269
- 募集
- Memorial Hospital East
-
コンタクト:
- Site Public Contact
- 電話番号:314-747-9912
- メール:dschwab@wustl.edu
-
主任研究者:
- Nancy L. Bartlett
-
Urbana、Illinois、アメリカ、61801
- 募集
- Carle Cancer Center
-
主任研究者:
- Suparna Mantha
-
コンタクト:
- Site Public Contact
- 電話番号:800-446-5532
- メール:Research@carle.com
-
-
Indiana
-
Crown Point、Indiana、アメリカ、46307
- 募集
- Northwest Cancer Center - Main Campus
-
主任研究者:
- Suparna Mantha
-
コンタクト:
- Site Public Contact
- 電話番号:219-310-2550
-
Dyer、Indiana、アメリカ、46311
- 募集
- Northwest Oncology LLC
-
主任研究者:
- Suparna Mantha
-
コンタクト:
- Site Public Contact
- 電話番号:219-924-8178
-
Hobart、Indiana、アメリカ、46342
- 募集
- Northwest Cancer Center - Hobart
-
主任研究者:
- Suparna Mantha
-
コンタクト:
- Site Public Contact
- 電話番号:219-947-1795
-
Hobart、Indiana、アメリカ、46342
- 募集
- Saint Mary Medical Center
-
主任研究者:
- Suparna Mantha
-
コンタクト:
- Site Public Contact
- 電話番号:219-836-6875
- メール:CancerResearch@COMHS.org
-
Indianapolis、Indiana、アメリカ、46312
- 募集
- Saint Catherine Hospital
-
主任研究者:
- Suparna Mantha
-
コンタクト:
- Site Public Contact
- メール:protocols@swog.org
-
Munster、Indiana、アメリカ、46321
- 募集
- The Community Hospital
-
主任研究者:
- Suparna Mantha
-
コンタクト:
- Site Public Contact
- 電話番号:219-836-3349
-
Munster、Indiana、アメリカ、46321
- 募集
- Women's Diagnostic Center - Munster
-
主任研究者:
- Suparna Mantha
-
コンタクト:
- Site Public Contact
- 電話番号:219-934-8869
- メール:mnicholson@comhs.org
-
Valparaiso、Indiana、アメリカ、46383
- 募集
- Northwest Cancer Center - Valparaiso
-
主任研究者:
- Suparna Mantha
-
コンタクト:
- Site Public Contact
- 電話番号:219-836-6875
- メール:CancerResearch@COMHS.org
-
-
Iowa
-
Ankeny、Iowa、アメリカ、50023
- 一時停止
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Cedar Rapids、Iowa、アメリカ、52403
- 募集
- Mercy Hospital
-
コンタクト:
- Site Public Contact
- 電話番号:319-365-4673
-
主任研究者:
- Deborah W. Wilbur
-
Cedar Rapids、Iowa、アメリカ、52403
- 募集
- Oncology Associates at Mercy Medical Center
-
主任研究者:
- Deborah W. Wilbur
-
コンタクト:
- Site Public Contact
- 電話番号:319-363-2690
-
Clive、Iowa、アメリカ、50325
- 一時停止
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Des Moines、Iowa、アメリカ、50314
- 募集
- Mercy Medical Center - Des Moines
-
主任研究者:
- Richard L. Deming
-
コンタクト:
- Site Public Contact
- 電話番号:515-358-6613
- メール:cancerresearch@mercydesmoines.org
-
Des Moines、Iowa、アメリカ、50314
- 一時停止
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48106
- 募集
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
コンタクト:
- Site Public Contact
- 電話番号:734-712-7251
- メール:MCRCwebsitecontactform@stjoeshealth.org
-
主任研究者:
- Tareq Al baghdadi
-
Brighton、Michigan、アメリカ、48114
- 募集
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
コンタクト:
- Site Public Contact
- 電話番号:734-712-7251
- メール:MCRCwebsitecontactform@stjoeshealth.org
-
主任研究者:
- Tareq Al baghdadi
-
Brighton、Michigan、アメリカ、48114
- 募集
- Trinity Health Medical Center - Brighton
-
コンタクト:
- Site Public Contact
- 電話番号:734-712-7251
- メール:MCRCwebsitecontactform@stjoeshealth.org
-
主任研究者:
- Tareq Al baghdadi
-
Canton、Michigan、アメリカ、48188
- 募集
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
コンタクト:
- Site Public Contact
- 電話番号:734-712-7251
- メール:MCRCwebsitecontactform@stjoeshealth.org
-
主任研究者:
- Tareq Al baghdadi
-
Canton、Michigan、アメリカ、48188
- 募集
- Trinity Health Medical Center - Canton
-
コンタクト:
- Site Public Contact
- 電話番号:734-712-7251
- メール:MCRCwebsitecontactform@stjoeshealth.org
-
主任研究者:
- Tareq Al baghdadi
-
Chelsea、Michigan、アメリカ、48118
- 募集
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
コンタクト:
- Site Public Contact
- 電話番号:734-712-7251
- メール:MCRCwebsitecontactform@stjoeshealth.org
-
主任研究者:
- Tareq Al baghdadi
-
Chelsea、Michigan、アメリカ、48118
- 募集
- Chelsea Hospital
-
コンタクト:
- Site Public Contact
- 電話番号:734-712-7251
- メール:MCRCwebsitecontactform@stjoeshealth.org
-
主任研究者:
- Tareq Al baghdadi
-
Flint、Michigan、アメリカ、48503
- 募集
- Genesys Hurley Cancer Institute
-
コンタクト:
- Site Public Contact
- 電話番号:810-762-8038
- メール:wstrong@ghci.org
-
主任研究者:
- Tareq Al baghdadi
-
Flint、Michigan、アメリカ、48503
- 募集
- Hurley Medical Center
-
コンタクト:
- Site Public Contact
- 電話番号:810-762-8038
- メール:wstrong@ghci.org
-
主任研究者:
- Tareq Al baghdadi
-
Flint、Michigan、アメリカ、48503
- 一時停止
- Genesee Hematology Oncology PC
-
Flint、Michigan、アメリカ、48503
- 募集
- Cancer Hematology Centers - Flint
-
コンタクト:
- Site Public Contact
- 電話番号:810-762-8038
- メール:wstrong@ghci.org
-
主任研究者:
- Tareq Al baghdadi
-
Lansing、Michigan、アメリカ、48912
- 募集
- University of Michigan Health - Sparrow Lansing
-
主任研究者:
- Tareq Al baghdadi
-
コンタクト:
- Site Public Contact
- 電話番号:517-364-3712
- メール:harsha.trivedi@umhsparrow.org
-
Livonia、Michigan、アメリカ、48154
- 募集
- Trinity Health Saint Mary Mercy Livonia Hospital
-
コンタクト:
- Site Public Contact
- 電話番号:734-712-7251
- メール:MCRCwebsitecontactform@stjoeshealth.org
-
主任研究者:
- Tareq Al baghdadi
-
Pontiac、Michigan、アメリカ、48341
- 募集
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
コンタクト:
- Site Public Contact
- 電話番号:734-712-7251
- メール:MCRCwebsitecontactform@stjoeshealth.org
-
主任研究者:
- Tareq Al baghdadi
-
Ypsilanti、Michigan、アメリカ、48106
- 募集
- Huron Gastroenterology PC
-
コンタクト:
- Site Public Contact
- 電話番号:734-712-7251
- メール:MCRCwebsitecontactform@stjoeshealth.org
-
主任研究者:
- Tareq Al baghdadi
-
Ypsilanti、Michigan、アメリカ、48197
- 募集
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
コンタクト:
- Site Public Contact
- 電話番号:734-712-7251
- メール:MCRCwebsitecontactform@stjoeshealth.org
-
主任研究者:
- Tareq Al baghdadi
-
-
Minnesota
-
Deer River、Minnesota、アメリカ、56636
- 募集
- Essentia Health - Deer River Clinic
-
コンタクト:
- Site Public Contact
- 電話番号:218-786-3308
- メール:CancerTrials@EssentiaHealth.org
-
主任研究者:
- Bret E. Friday
-
Duluth、Minnesota、アメリカ、55805
- 募集
- Essentia Health Cancer Center
-
コンタクト:
- Site Public Contact
- 電話番号:218-786-3308
- メール:CancerTrials@EssentiaHealth.org
-
主任研究者:
- Bret E. Friday
-
Hibbing、Minnesota、アメリカ、55746
- 募集
- Essentia Health Hibbing Clinic
-
主任研究者:
- Bret E. Friday
-
コンタクト:
- Site Public Contact
- 電話番号:218-786-3308
-
Sandstone、Minnesota、アメリカ、55072
- 募集
- Essentia Health Sandstone
-
コンタクト:
- Site Public Contact
- 電話番号:218-786-3308
- メール:CancerTrials@EssentiaHealth.org
-
主任研究者:
- Bret E. Friday
-
Virginia、Minnesota、アメリカ、55792
- 募集
- Essentia Health Virginia Clinic
-
コンタクト:
- Site Public Contact
- 電話番号:218-786-3308
- メール:CancerTrials@EssentiaHealth.org
-
主任研究者:
- Bret E. Friday
-
-
Mississippi
-
Jackson、Mississippi、アメリカ、39216
- 募集
- University of Mississippi Medical Center
-
コンタクト:
- Site Public Contact
- 電話番号:601-815-6700
-
主任研究者:
- Carrie K. Wynn
-
-
Missouri
-
City of Saint Peters、Missouri、アメリカ、63376
- 募集
- Siteman Cancer Center at Saint Peters Hospital
-
主任研究者:
- Nancy L. Bartlett
-
コンタクト:
- Site Public Contact
- 電話番号:800-600-3606
- メール:info@siteman.wustl.edu
-
Creve Coeur、Missouri、アメリカ、63141
- 募集
- Siteman Cancer Center at West County Hospital
-
主任研究者:
- Nancy L. Bartlett
-
コンタクト:
- Site Public Contact
- 電話番号:800-600-3606
- メール:info@siteman.wustl.edu
-
St Louis、Missouri、アメリカ、63110
- 募集
- Washington University School of Medicine
-
主任研究者:
- Nancy L. Bartlett
-
コンタクト:
- Site Public Contact
- 電話番号:800-600-3606
- メール:info@siteman.wustl.edu
-
St Louis、Missouri、アメリカ、63129
- 募集
- Siteman Cancer Center-South County
-
主任研究者:
- Nancy L. Bartlett
-
コンタクト:
- Site Public Contact
- 電話番号:800-600-3606
- メール:info@siteman.wustl.edu
-
St Louis、Missouri、アメリカ、63136
- 募集
- Siteman Cancer Center at Christian Hospital
-
主任研究者:
- Nancy L. Bartlett
-
コンタクト:
- Site Public Contact
- 電話番号:800-600-3606
- メール:info@siteman.wustl.edu
-
-
New York
-
New York、New York、アメリカ、10032
- 募集
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
主任研究者:
- Jennifer E. Amengual
-
コンタクト:
- Site Public Contact
- 電話番号:212-342-5162
- メール:cancerclinicaltrials@cumc.columbia.edu
-
Rochester、New York、アメリカ、14642
- 募集
- University of Rochester
-
コンタクト:
- Site Public Contact
- 電話番号:585-275-5830
-
主任研究者:
- Patrick M. Reagan
-
Webster、New York、アメリカ、14580
- 募集
- Wilmot Cancer Institute at Webster
-
コンタクト:
- Site Public Contact
- メール:WCICTOresearch@urmc.rochester.edu
-
主任研究者:
- Patrick M. Reagan
-
-
Oklahoma
-
Oklahoma City、Oklahoma、アメリカ、73104
- 募集
- University of Oklahoma Health Sciences Center
-
コンタクト:
- Site Public Contact
- 電話番号:405-271-8777
- メール:ou-clinical-trials@ouhsc.edu
-
主任研究者:
- Taha Al-Juhaishi
-
-
Oregon
-
Newberg、Oregon、アメリカ、97132
- 募集
- Providence Newberg Medical Center
-
コンタクト:
- Site Public Contact
- 電話番号:503-215-2614
- メール:CanRsrchStudies@providence.org
-
主任研究者:
- Charles W. Drescher
-
Oregon City、Oregon、アメリカ、97045
- 募集
- Providence Willamette Falls Medical Center
-
コンタクト:
- Site Public Contact
- 電話番号:503-215-2614
- メール:CanRsrchStudies@providence.org
-
主任研究者:
- Charles W. Drescher
-
Portland、Oregon、アメリカ、97213
- 募集
- Providence Portland Medical Center
-
コンタクト:
- Site Public Contact
- 電話番号:503-215-2614
- メール:CanRsrchStudies@providence.org
-
主任研究者:
- Charles W. Drescher
-
Portland、Oregon、アメリカ、97225
- 募集
- Providence Saint Vincent Medical Center
-
コンタクト:
- Site Public Contact
- 電話番号:503-215-2614
- メール:CanRsrchStudies@providence.org
-
主任研究者:
- Charles W. Drescher
-
-
South Carolina
-
Charleston、South Carolina、アメリカ、29425
- 募集
- Medical University of South Carolina
-
コンタクト:
- Site Public Contact
- 電話番号:843-792-9321
- メール:hcc-clinical-trials@musc.edu
-
主任研究者:
- Brian T. Hess
-
-
Texas
-
Houston、Texas、アメリカ、77030
- 募集
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
コンタクト:
- Site Public Contact
- 電話番号:713-798-1354
- メール:burton@bcm.edu
-
主任研究者:
- Akiva Diamond
-
Houston、Texas、アメリカ、77030
- 募集
- Ben Taub General Hospital
-
コンタクト:
- Site Public Contact
- 電話番号:713-873-2000
-
主任研究者:
- Akiva Diamond
-
San Antonio、Texas、アメリカ、78229
- 募集
- University of Texas Health Science Center at San Antonio
-
コンタクト:
- Site Public Contact
- 電話番号:210-450-3800
- メール:phoresearchoffice@uthscsa.edu
-
主任研究者:
- Adolfo E. Diaz Duque
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84112
- 募集
- Huntsman Cancer Institute/University of Utah
-
コンタクト:
- Site Public Contact
- 電話番号:888-424-2100
- メール:cancerinfo@hci.utah.edu
-
主任研究者:
- Allison Bock
-
-
Virginia
-
Richmond、Virginia、アメリカ、23235
- 募集
- VCU Massey Cancer Center at Stony Point
-
主任研究者:
- Victor Y. Yazbeck
-
コンタクト:
- Site Public Contact
- メール:ctoclinops@vcu.edu
-
Richmond、Virginia、アメリカ、23298
- 募集
- VCU Massey Comprehensive Cancer Center
-
主任研究者:
- Victor Y. Yazbeck
-
コンタクト:
- Site Public Contact
- 電話番号:804-628-6430
- メール:CTOclinops@vcu.edu
-
-
Wisconsin
-
Appleton、Wisconsin、アメリカ、54911
- 募集
- ThedaCare Regional Cancer Center
-
コンタクト:
- Site Public Contact
- 電話番号:920-364-3604
- メール:ResearchDept@thedacare.org
-
主任研究者:
- Yazhini Vallatharasu
-
Ashland、Wisconsin、アメリカ、54806
- 募集
- Duluth Clinic Ashland
-
コンタクト:
- Site Public Contact
- 電話番号:218-786-3308
- メール:CancerTrials@EssentiaHealth.org
-
主任研究者:
- Bret E. Friday
-
Burlington、Wisconsin、アメリカ、53105
- 募集
- Aurora Cancer Care-Southern Lakes VLCC
-
コンタクト:
- Site Public Contact
- 電話番号:414-302-2304
- メール:ncorp@aurora.org
-
主任研究者:
- Thomas J. Saphner
-
Eau Claire、Wisconsin、アメリカ、54701
- 募集
- Marshfield Medical Center-EC Cancer Center
-
コンタクト:
- Site Public Contact
- 電話番号:800-782-8581
- メール:oncology.clinical.trials@marshfieldresearch.org
-
主任研究者:
- Dean A. Delmastro
-
Germantown、Wisconsin、アメリカ、53022
- 募集
- Aurora Health Care Germantown Health Center
-
コンタクト:
- Site Public Contact
- 電話番号:414-302-2304
- メール:ncorp@aurora.org
-
主任研究者:
- Thomas J. Saphner
-
Grafton、Wisconsin、アメリカ、53024
- 募集
- Aurora Cancer Care-Grafton
-
コンタクト:
- Site Public Contact
- 電話番号:414-302-2304
- メール:ncorp@aurora.org
-
主任研究者:
- Thomas J. Saphner
-
Green Bay、Wisconsin、アメリカ、54311
- 募集
- Aurora BayCare Medical Center
-
コンタクト:
- Site Public Contact
- 電話番号:414-302-2304
- メール:ncorp@aurora.org
-
主任研究者:
- Thomas J. Saphner
-
Kenosha、Wisconsin、アメリカ、53142
- 募集
- Aurora Cancer Care-Kenosha South
-
コンタクト:
- Site Public Contact
- 電話番号:414-302-2304
- メール:ncorp@aurora.org
-
主任研究者:
- Thomas J. Saphner
-
La Crosse、Wisconsin、アメリカ、54601
- 募集
- Gundersen Lutheran Medical Center
-
コンタクト:
- Site Public Contact
- 電話番号:608-775-2385
- メール:cancerctr@gundersenhealth.org
-
主任研究者:
- David E. Marinier
-
Marinette、Wisconsin、アメリカ、54143
- 募集
- Aurora Bay Area Medical Group-Marinette
-
コンタクト:
- Site Public Contact
- 電話番号:414-302-2304
- メール:ncorp@aurora.org
-
主任研究者:
- Thomas J. Saphner
-
Marshfield、Wisconsin、アメリカ、54449
- 募集
- Marshfield Medical Center-Marshfield
-
コンタクト:
- Site Public Contact
- 電話番号:800-782-8581
- メール:oncology.clinical.trials@marshfieldresearch.org
-
主任研究者:
- Dean A. Delmastro
-
Milwaukee、Wisconsin、アメリカ、53209
- 募集
- Aurora Cancer Care-Milwaukee
-
コンタクト:
- Site Public Contact
- 電話番号:414-302-2304
- メール:ncorp@aurora.org
-
主任研究者:
- Thomas J. Saphner
-
Milwaukee、Wisconsin、アメリカ、53215
- 募集
- Aurora Saint Luke's Medical Center
-
コンタクト:
- Site Public Contact
- 電話番号:414-302-2304
- メール:ncorp@aurora.org
-
主任研究者:
- Thomas J. Saphner
-
Milwaukee、Wisconsin、アメリカ、53233
- 募集
- Aurora Sinai Medical Center
-
コンタクト:
- Site Public Contact
- 電話番号:414-302-2304
- メール:ncorp@aurora.org
-
主任研究者:
- Thomas J. Saphner
-
Minocqua、Wisconsin、アメリカ、54548
- 募集
- Marshfield Medical Center - Minocqua
-
コンタクト:
- Site Public Contact
- 電話番号:800-782-8581
- メール:oncology.clinical.trials@marshfieldresearch.org
-
主任研究者:
- Dean A. Delmastro
-
Oshkosh、Wisconsin、アメリカ、54904
- 募集
- Vince Lombardi Cancer Clinic - Oshkosh
-
コンタクト:
- Site Public Contact
- 電話番号:414-302-2304
- メール:ncorp@aurora.org
-
主任研究者:
- Thomas J. Saphner
-
Racine、Wisconsin、アメリカ、53406
- 募集
- Aurora Cancer Care-Racine
-
コンタクト:
- Site Public Contact
- 電話番号:414-302-2304
- メール:ncorp@aurora.org
-
主任研究者:
- Thomas J. Saphner
-
Rice Lake、Wisconsin、アメリカ、54868
- 募集
- Marshfield Medical Center-Rice Lake
-
コンタクト:
- Site Public Contact
- 電話番号:800-782-8581
- メール:oncology.clinical.trials@marshfieldresearch.org
-
主任研究者:
- Dean A. Delmastro
-
Sheboygan、Wisconsin、アメリカ、53081
- 募集
- Vince Lombardi Cancer Clinic-Sheboygan
-
コンタクト:
- Site Public Contact
- 電話番号:414-302-2304
- メール:ncorp@aurora.org
-
主任研究者:
- Thomas J. Saphner
-
Stevens Point、Wisconsin、アメリカ、54482
- 募集
- Marshfield Medical Center-River Region at Stevens Point
-
コンタクト:
- Site Public Contact
- 電話番号:800-782-8581
- メール:oncology.clinical.trials@marshfieldresearch.org
-
主任研究者:
- Dean A. Delmastro
-
Summit、Wisconsin、アメリカ、53066
- 募集
- Aurora Medical Center in Summit
-
コンタクト:
- Site Public Contact
- 電話番号:414-302-2304
- メール:ncorp@aurora.org
-
主任研究者:
- Thomas J. Saphner
-
Two Rivers、Wisconsin、アメリカ、54241
- 募集
- Vince Lombardi Cancer Clinic-Two Rivers
-
コンタクト:
- Site Public Contact
- 電話番号:414-302-2304
- メール:ncorp@aurora.org
-
主任研究者:
- Thomas J. Saphner
-
Wauwatosa、Wisconsin、アメリカ、53226
- 募集
- Aurora Cancer Care-Milwaukee West
-
コンタクト:
- Site Public Contact
- 電話番号:414-302-2304
- メール:ncorp@aurora.org
-
主任研究者:
- Thomas J. Saphner
-
West Allis、Wisconsin、アメリカ、53227
- 募集
- Aurora West Allis Medical Center
-
コンタクト:
- Site Public Contact
- 電話番号:414-302-2304
- メール:ncorp@aurora.org
-
主任研究者:
- Thomas J. Saphner
-
Weston、Wisconsin、アメリカ、54476
- 募集
- Marshfield Medical Center - Weston
-
コンタクト:
- Site Public Contact
- 電話番号:800-782-8581
- メール:oncology.clinical.trials@marshfieldresearch.org
-
主任研究者:
- Dean A. Delmastro
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Participants must have:
- Histologically confirmed relapsed/refractory LBCL as outlined by the World Health Organization (WHO) guidelines
- Follicular lymphoma, grade 3B
- Transformed lymphoma
- High grade B-cell lymphoma with or without MYC, BCL2 and/or BCL6 rearrangements
-
Participants must have staging imaging performed within 28 days prior to registration, as follows. Positron emission tomography (PET)-computed tomography (CT) baseline scans are strongly preferred; diagnostic quality magnetic resonance imaging (MRI), contrast-enhanced CT, or contrast-enhanced MRI scans are also acceptable if PET-CT is not feasible at baseline. Note: PET-CT will be required at end of treatment (EOT) and progression for response assessment. All measurable lesions (longest diameter >= 1.5 cm) must be assessed within 28 days prior to registration. Tests to assess non-measurable disease must be performed within 28 days prior to registration. All disease must be documented on the Baseline Tumor Assessment Form.
-
Participants must have cell of origin (COO) determination of germinal center (GC)(GCB or non-GC GCB) of LBCL based on Hans immunohistochemistry algorithm (CD10, BCL6, MUM1) as noted on pathology report.
-
Participants must have had 1-5 prior systemic treatment regimens including one systemic multiagent regimen for aggressive lymphoma
-
Participants who have received prior systemic therapy must have completed their last treatment prior to registration. Participants must have recovered from previous therapy
-
Steroid use for the control of non-Hodgkin lymphoma symptoms is allowable, but must be discontinued prior to Cycle 1, Day 1
-
Participant must be >= 18 years old
-
Participant must have Zubrod Performance Status of 0-3
-
Participant must have a complete medical history and physical exam within 28 days prior to registration
-
Absolute neutrophil count >= 1.0 x 10^3/uL (within 28 days prior to registration)
- If there is documented lymphomatous involvement of the bone marrow as assessed by bone marrow biopsy within 90 days prior to registration, participants must have: Absolute neutrophil count (ANC) >= 0.75 x 10^3/uL
-
Platelets >= 75 x 10^3/uL (within 28 days prior to registration)
- If there is documented lymphomatous involvement of the bone marrow as assessed by bone marrow biopsy within 90 days prior to registration, participants must have: Platelets >= 50 x 10^3/uL
-
Aspartate aminotransferase (AST) =< 3 x institutional upper limit of normal (IULN), alanine aminotransferase (ALT) =< 3 x IULN (within 28 days prior to registration) unless due to Gilbert's disease, hemolysis, or lymphomatous involvement of liver.
- Participants with lymphomatous involvement of the liver must have AST =< 5 x IULN, ALT =< 5 x IULN
-
Total bilirubin =< 1.5 x IULN (within 28 days prior to registration) unless due to Gilbert's disease, hemolysis, or lymphomatous involvement of liver.
- Participants with lymphomatous involvement of the liver must have total bilirubin =< 5 x IULN
-
Participants must have a calculated creatinine clearance >= 30 mL/min using the following Cockcroft-Gault Formula. This specimen must have been drawn and processed within 28 days prior to registration
-
Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
-
Participants must have recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1) with the exception of alopecia
-
Participants with known human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy at randomization and have undetectable viral load test on the most recent test results obtained within 6 months prior to registration
-
Participants with evidence of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load on the most recent test results obtained within the last year and received suppressive therapy
-
Participants with a history of hepatitis C virus (HCV) infection must have an undetectable viral load. Participants currently being treated for HCV infection must have undetectable HCV viral load test on the most recent test results obtained within 28 days prior to registration
-
Participants must be able to swallow and retain orally administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption, such as malabsorption syndrome or major resection of the stomach or bowels
-
Participants must be offered the opportunity to participate in specimen banking. With participant consent, specimens must be collected and submitted via the Southwest Oncology Group (SWOG) Specimen Tracking System
-
Participants who can complete the FACT-Lym and PRO-CTCAE forms in English or Spanish must agree to participate in the patient-reported outcome study
-
Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines.
- For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and central institutional review board (CIRB) regulations.
Exclusion Criteria:
-
Participants must not have active lymphomatous involvement of the central nervous system (CNS) because the treatments used in this study are not effective to sufficiently penetrate the blood brain barrier
-
Participants must not have known abnormalities associated with myelodysplastic syndrome (MDS) (e.g., del 5q, chr 7 abn) and myeloproliferative neoplasms (MPN) (e.g., JAK2 V617F) observed in cytogenetic testing and deoxyribonucleic acid (DNA) sequencing. Testing is not required for eligibility determination
-
Participants must not have a known prior history of T-cell lymphoblastic lymphoma (T-LBL)/T-cell acute leukemia (T-ALL). Testing is not required for eligibility determination
-
Participants must not be a candidate based on investigator assessment to receive autologous stem cell transplant (ASCT) or must have declined ASCT. Participants who had disease progression after stem cell transplant or cellular therapy (such as chimeric antigen receptor (CAR) T-cell) are eligible
-
Participants must not have received prior treatment with tafasitamab and/or lenalidomide
-
Participants must not have had prior BTK inhibitor or tazemetostat
-
Participants must not have any known allergy or reaction to any component of tafasitamab, lenalidomide, tazemetostat or zanubrutinib
-
Participants must not be receiving direct vitamin K inhibitors or strong or moderate CYP3A inhibitors or inducers at the date of registration
- Notes: Because the list of these agents is constantly changing, it is important to regularly consult a frequently updated medical reference
-
Participants must not have a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) has the potential to interfere with the safety or efficacy assessment of the investigational regimen
-
Participants must not be pregnant or nursing and must follow the guidelines according to the lenalidomide Risk Evaluation and Mitigation Strategies (REMS) program. The effects of tazemetostat, zanubrutinib, lenalidomide and tafasitamab, and the combination of these drugs have not been studied on the developing human fetus are the effects are unknown. Individuals who are of reproductive potential must have agreed to use a highly effective contraceptive method with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential". In addition to routine contraceptive methods, "acceptable contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Part I, Arm I (tafasitamab, lenalidomide, tazemetostat)
Patients receive tafasitamab IV, lenalidomide PO, and tazemetostat PO on study. Patients also undergo PET/CT and CT or MRI scans throughout the trial. Patients also have the option to undergo collection of blood samples during screening and on study. |
Ancillary studies
他の名前:
Given PO
他の名前:
Undergo MRI
他の名前:
Undergo PET/CT
他の名前:
Given PO
他の名前:
Given IV
他の名前:
Undergo PET/CT and CT
他の名前:
Undergo optional collection of blood
他の名前:
|
|
実験的:Part I, Arm III (tafasitamab, lenalidomide, zanubrutinib)
Patients receive tafasitamab IV, lenalidomide PO, and zanubrutinib PO on study. Patients also undergo PET/CT and CT or MRI scans throughout the trial. Patients also have the option to undergo collection of blood samples during screening and on study. |
Ancillary studies
他の名前:
Given PO
他の名前:
Undergo MRI
他の名前:
Ancillary studies Undergo PET/CT
他の名前:
Given IV
他の名前:
Undergo PET/CT and CT
他の名前:
Given PO
他の名前:
Undergo optional collection of blood
他の名前:
|
|
実験的:Part II, Arm I (tafasitamab, lenalidomide, tazemetostat)
Patients receive tafasitamab IV, lenalidomide PO, and tazemetostat PO on study. Patients also undergo PET/CT and CT or MRI scans throughout the trial. Patients also have the option to undergo collection of blood samples during screening and on study. |
Ancillary studies
他の名前:
Given PO
他の名前:
Undergo MRI
他の名前:
Ancillary studies Undergo PET/CT
他の名前:
Given PO
他の名前:
Given IV
他の名前:
Undergo PET/CT and CT
他の名前:
Undergo optional collection of blood
他の名前:
|
|
アクティブコンパレータ:Part II, Arm II (tafasitamab, lenalidomide)
Patients receive tafasitamab IV and lenalidomide PO on study. Patients also undergo PET/CT and CT or MRI scans throughout the trial. Patients also have the option to undergo collection of blood samples during screening and on study. |
Ancillary studies
他の名前:
Given PO
他の名前:
Undergo MRI
他の名前:
Ancillary studies Undergo PET/CT
他の名前:
Given IV
他の名前:
Undergo PET/CT and CT
他の名前:
Undergo optional collection of blood
他の名前:
|
|
実験的:Part II, Arm III (tafasitamab, lenalidomide, zanubrutinib)
Patients receive tafasitamab IV, lenalidomide PO, and zanubrutinib PO on study. Patients also undergo PET/CT and CT or MRI scans throughout the trial. Patients also have the option to undergo collection of blood samples during screening and on study. |
Ancillary studies
他の名前:
Given PO
他の名前:
Undergo MRI
他の名前:
Ancillary studies Undergo PET/CT
他の名前:
Given IV
他の名前:
Undergo PET/CT and CT
他の名前:
Given PO
他の名前:
Undergo optional collection of blood
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression-free survival (PFS)
時間枠:From date of randomization to date of first observation of progressive disease according to the 2014 Lugano classification, or death due to any cause, assessed up to 3 years
|
Will be compared between participants randomized to control Arm 2 (tafasitamab + lenalidomide) versus (vs) experimental Arm 1 (tafasitamab + lenalidomide + tazemetostat), AND control Arm 2 vs experimental Arm 3 (tafasitamab + lenalidomide + zanubrutinib), respectively. |
From date of randomization to date of first observation of progressive disease according to the 2014 Lugano classification, or death due to any cause, assessed up to 3 years
|
|
Trial Outcome Index (TOI) score from the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) (Patient Reported Outcome [PRO] Study)
時間枠:Baseline up to 3 months after randomization
|
Will compare the trial outcome index (TOI) score between each experimental arm (Arm 1 and Arm 3) to the control arm (Arm 2). The TOI score is composed of the Physical Well-Being, Functional Well-Being, and lymphoma-specific subscale scores. The scores range from 0-116, with higher scores indicating a higher quality of life. |
Baseline up to 3 months after randomization
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Hazard ratio for PFS in the germinal center B-cell (GCB) subgroup
時間枠:Up to 3 years
|
Will calculate the 80% confidence interval (CI) for the Cox regression time-to-event estimate of the hazard ratio associated with addition of tazemetostat to tafasitamab+lenalidomide combination (Arm 2 vs Arm 1) in the GCB subgroup. If the confidence interval excludes 1, then 80% CI will be calculated for the non-GCB group. |
Up to 3 years
|
|
Hazard ratio for PFS in the non-GCB subgroup
時間枠:Up to 3 years
|
Will calculate the 80% CI for the hazard ratio associated with addition of zanubrutinib to tafasitamab+lenalidomide combination (Arm 2 vs Arm 3) in the non-GCB subgroup. If the confidence interval excludes 1, then 80% CI will be calculated for the GCB group. |
Up to 3 years
|
|
PFS
時間枠:From date of randomization to date of first observation of progressive disease according to the 2014 Lugano classification, or death due to any cause, assessed up to 3 years
|
Will estimate in GCB and non-GCB large B-cell lymphoma (LBCL) for each treatment. Will be estimated using the method of Kaplan-Meier and 80% confidence interval will be calculated. |
From date of randomization to date of first observation of progressive disease according to the 2014 Lugano classification, or death due to any cause, assessed up to 3 years
|
|
Overall response rate (ORR)
時間枠:Up to 3 years
|
Will estimate in GCB and non-GCB LBCL for each treatment. Will be estimated using the method of Kaplan-Meier and 80% confidence interval will be calculated. |
Up to 3 years
|
|
Complete response (CR) rate
時間枠:Up to 3 years
|
Will estimate in GCB and non-GCB LBCL for each treatment. Will be estimated using the method of Kaplan-Meier and 80% confidence interval will be calculated. |
Up to 3 years
|
|
Partial response (PR) rate
時間枠:Up to 3 years
|
Will estimate in GCB and non-GCB LBCL for each treatment. Will be estimated using the method of Kaplan-Meier and 80% confidence interval will be calculated. |
Up to 3 years
|
|
Duration of response (DOR)
時間枠:From date of first documentation of response to treatment (CR, PR) to date of first documentation of progression, or death due to any cause among patients who achieve a response (CR or PR), assessed up to 3 years
|
Will estimate in GCB and non-GCB LBCL for each treatment. Will be estimated using the method of Kaplan-Meier and 80% confidence interval will be calculated. |
From date of first documentation of response to treatment (CR, PR) to date of first documentation of progression, or death due to any cause among patients who achieve a response (CR or PR), assessed up to 3 years
|
|
Event free survival (EFS)
時間枠:From date of randomization to date of first occurrence of EFS event, assessed up to 3 years
|
Will estimate in GCB and non-GCB LBCL for each treatment. Will be estimated using the method of Kaplan-Meier and 80% confidence interval will be calculated. |
From date of randomization to date of first occurrence of EFS event, assessed up to 3 years
|
|
Overall survival (OS)
時間枠:From date of randomization to date of death due to any cause, assessed up to 3 years
|
Will estimate in GCB and non-GCB LBCL for each treatment. Will be estimated using the method of Kaplan-Meier and 80% confidence interval will be calculated. |
From date of randomization to date of death due to any cause, assessed up to 3 years
|
|
Incidence of adverse events
時間枠:Up to 3 years
|
Will be evaluated using the Common Terminology Criteria for Adverse Events (CTCAE) Version 5. Eligible participants receiving at least one dose of drug will be included in the assessment of adverse events by treatment arms. The maximum Grade for each toxicity will be recorded for each participant, and frequency tables will be reviewed to determine toxicity patterns. With 60 eligible participants in each arm, any toxicity occurring with at least 5% probability is likely to be seen at least once (95% chance). Toxicity rates in each arm can be estimated to within at least +/- 13% with 95% confidence. |
Up to 3 years
|
協力者と研究者
捜査官
- 主任研究者:Jennifer E Amengual、SWOG Cancer Research Network
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 新生物
- 免疫系疾患
- 組織型別の新生物
- リンパ疾患
- リンパ増殖性疾患
- 免疫増殖性疾患
- リンパ腫、非ホジキン
- リンパ腫、B細胞
- リンパ腫
- ヘミックおよびリンパ疾患
- リンパ腫、大型B細胞、びまん性
- アミノ酸、ペプチド、およびタンパク質
- タンパク質
- 硫黄化合物
- 有機化学物質
- 複素環化化合物、1リング
- 複素環化化合物
- 複素環化化合物、2リング
- 複素環化化合物、融合リング
- 調査手法
- 臨床検査技術
- 診断技術と手順
- 診断
- カルボン酸
- ピペリジン
- 免疫タンパク質
- 血液タンパク質
- 血清グロブリン
- グロブリン
- 無機化学物質
- 化学技術、分析
- スペクトル分析
- 硫化物
- 陰イオン
- イオン
- 電解質
- 硫化水素
- フタリミド
- フタル酸
- 酸、炭素環
- ピペリドン
- イソインドール
- レナリドミド
- 免疫グロブリン
- zanubrutinib
- 標本処理
- 磁気共鳴分光法
- ジスルフィド
- タファシタマブ
- Tazemetostat
その他の研究ID番号
- S2207
- U10CA180888 (米国 NIH グラント/契約)
- S2207 (その他の識別子:CTEP)
- NCI-2023-02518 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
- S2207 (その他の識別子:SWOG)
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。